Clinical Trials Logo

Clinical Trial Summary

Gilteritinib is available in early access in France through Temporary Authorisation of Use (or ATU program) since March 2019. The ATU program reflects a real-life treatment situation and the related clinical data would help to better understand the benefit/risk profile of gilteritinib and to better document gilteritinib efficacy and safety in patients who received midostaurine in 1L setting. The main objective is to describe gilteritinib effectiveness in FLT3-mutated AML patients in R/R situation treated in the context of early access program to gilteritinib in France through Temporary Authorisation of Use, the so-called ATU program, and the post ATU period from marketing authorisation to launch when reimbursement and price are published.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05193448
Study type Observational [Patient Registry]
Source French Innovative Leukemia Organisation
Contact
Status Active, not recruiting
Phase
Start date July 30, 2021
Completion date January 31, 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03932318 - Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients Phase 1/Phase 2
Recruiting NCT05029141 - New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Phase 2
Active, not recruiting NCT03848754 - Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT04722952 - PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML Phase 3
Recruiting NCT04310592 - Natural Killer Cell (CYNK-001) Infusions in Adults With AML Phase 1
Recruiting NCT04139434 - Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML Phase 1
Recruiting NCT03867682 - Venetoclax and Lintuzumab-Ac225 in AML Patients Phase 1/Phase 2
Recruiting NCT03091933 - Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) Phase 1/Phase 2
Recruiting NCT04330820 - Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) Phase 1/Phase 2
Approved for marketing NCT03245424 - Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation